Niva Bupa Health Insurance Company Limited has informed the Exchange about Grant of Stock options under Niva Bupa Employee Stock Option Plan 2024.
NIVABUPA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Niva Bupa's Board meeting on May 8, 2026 resulted in four key outcomes: (1) Appointment of two new Non-Executive Additional Directors – Mr. Christopher Patrick Carroll (CEO of Bupa Global, India & UK) and Ms. Siobhan Djihan Moynihan (CFO of Bupa Global, India & UK), both effective May 15, 2026, subject to shareholder approval within 3 months. (2) Elevation of Mr. Ankur Kharbanda from Executive Director & Chief Business Officer to Executive Director & Deputy CEO, effective May 8, 2026. (3) Grant of 12,251,268 employee stock options (ESOPs) to eligible employees under the Niva Bupa ESOP Scheme 2024, at a grant price of ₹72.45 per option, compliant with SEBI (SBEB) Regulations 2021. (4) Resignation of two Non-Executive Directors – Ms. Penelope Ruth Dudley and Mr. Carlos Antonio Jaureguizar Ruiz-Jarabo – effective close of business hours on May 8, 2026, citing insufficient time due to other professional commitments.
The appointment of two senior Bupa global executives as directors and the internal promotion of Ankur Kharbanda to Deputy CEO signal a strengthened leadership bench. The large ESOP grant of 12.25 million options aligns employee interests with shareholders. The simultaneous resignation of two directors suggests a planned transition in board composition rather than any governance concern.